Equity Profile

STVN

Stevanato Group S.p.A.

Health CareLife Sciences Tools & Services$5.4B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Stevanato Group S.p.A. is a healthcare company that specializes in providing glass and plastic packaging solutions for the pharmaceutical and biotech industries....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs and generating profit.

N/A

Revenue Growth

Revenue growth reflects the company's ability to increase sales and capture market share, which is vital for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

STVN Q2-2026 Earnings Preview

Context

Company Snapshot

Stevanato Group S.p.A. is a healthcare company that specializes in providing glass and plastic packaging solutions for the pharmaceutical and biotech industries. With a market cap of $5 billion, it plays a crucial role in the life sciences sector, particularly as demand for innovative drug delivery systems continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+4.93%

Avg Stock Reaction

+4.40%

Last Quarter Recap

In Q1 2026, Stevanato Group reported an EPS of $0.13, slightly beating expectations. However, the stock fell 5.11% the following day, indicating mixed investor sentiment.

Management Promises & Guidance

Focus on expanding product offerings in the biotech sector.
Commitment to improving operational efficiencies.
Plans to enhance customer engagement and support.

Expectations

Wall Street Expectations

Overall expectations for Stevanato Group's upcoming earnings are cautious, given the mixed performance in previous quarters. Investors are looking for signs of sustained growth and profitability.

Bull Case

If the company reports strong revenue growth and maintains or improves its EPS, it could signal a positive trend and boost investor confidence.

Bear Case

Conversely, any signs of declining sales or increased costs could lead to further stock price declines, especially if the EPS falls short of expectations.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

EPS is a critical measure of profitability and will significantly influence market sentiment and stock performance.

How is revenue growth trending in the biotech sector?

Understanding revenue trends will help gauge the company's market position and future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for revenue growth in the biotech sector, especially given Stevanato's recent product expansions.

Supporting Evidence

The company's historical performance indicates a strong ability to exceed EPS expectations.

Options pricing suggests a significant move, indicating that investors are anticipating volatility.

Past earnings reactions show that positive surprises have led to stock gains despite initial declines.

Key Risk

If revenue growth exceeds 10%, it could shift the narrative significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the company's ability to sustain growth in a competitive environment, with both revenue and EPS being critical indicators.

Bull Confirmed If

A revenue growth rate exceeding 10% year-over-year would confirm the bull case.

Bear Confirmed If

A decline in revenue or an EPS below $0.10 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±34.08%

Historical Avg

±8.7%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±34.1% while STVN has averaged ±8.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

36.1%

Calls (300)P/C Ratio: 0.11Puts (300)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Stevanato beats expectations, history suggests the stock could rise around 1.1% on the first day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but management provides cautious commentary, the stock may experience muted movement.

Miss

Should the company miss expectations, history suggests a potential decline of around 13.55% on the first day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in the biotech sector.
2Insights into operational efficiencies and cost management strategies.
3Management's outlook on market demand and competitive landscape.
4Details on customer engagement initiatives and their impact on sales.
5Any commentary on supply chain challenges and mitigation strategies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Stevanato Group S.p.A. is a healthcare company that specializes in providing glass and plastic packaging solutions for the pharmaceutical and biotech industries....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs and generating profit.

N/A

Revenue Growth

Revenue growth reflects the company's ability to increase sales and capture market share, which is vital for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

STVN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+4.93%

Avg Stock Reaction

+4.40%

Last Quarter Recap

In Q1 2026, Stevanato Group reported an EPS of $0.13, slightly beating expectations. However, the stock fell 5.11% the following day, indicating mixed investor sentiment.

Management Promises & Guidance

Focus on expanding product offerings in the biotech sector.
Commitment to improving operational efficiencies.
Plans to enhance customer engagement and support.

Expectations

Wall Street Expectations

Overall expectations for Stevanato Group's upcoming earnings are cautious, given the mixed performance in previous quarters. Investors are looking for signs of sustained growth and profitability.

Bull Case

If the company reports strong revenue growth and maintains or improves its EPS, it could signal a positive trend and boost investor confidence.

Bear Case

Conversely, any signs of declining sales or increased costs could lead to further stock price declines, especially if the EPS falls short of expectations.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

EPS is a critical measure of profitability and will significantly influence market sentiment and stock performance.

How is revenue growth trending in the biotech sector?

Understanding revenue trends will help gauge the company's market position and future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for revenue growth in the biotech sector, especially given Stevanato's recent product expansions.

Supporting Evidence

The company's historical performance indicates a strong ability to exceed EPS expectations.

Options pricing suggests a significant move, indicating that investors are anticipating volatility.

Past earnings reactions show that positive surprises have led to stock gains despite initial declines.

Key Risk

If revenue growth exceeds 10%, it could shift the narrative significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the company's ability to sustain growth in a competitive environment, with both revenue and EPS being critical indicators.

Bull Confirmed If

A revenue growth rate exceeding 10% year-over-year would confirm the bull case.

Bear Confirmed If

A decline in revenue or an EPS below $0.10 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±34.08%

Historical Avg

±8.7%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±34.1% while STVN has averaged ±8.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

36.1%

Calls (300)P/C Ratio: 0.11Puts (300)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Stevanato beats expectations, history suggests the stock could rise around 1.1% on the first day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but management provides cautious commentary, the stock may experience muted movement.

Miss

Should the company miss expectations, history suggests a potential decline of around 13.55% on the first day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in the biotech sector.
2Insights into operational efficiencies and cost management strategies.
3Management's outlook on market demand and competitive landscape.
4Details on customer engagement initiatives and their impact on sales.
5Any commentary on supply chain challenges and mitigation strategies.